DATE: 02/21/2020
LOCATION: Education Resource Center Auditorium
TIME: 12:00 – 12:15 Pick Up Lunch
12:15 - 1:15 Department Update/Grand Rounds Lecture
TITLE: “Type 2 Diabetes Treatment 20/20”
Speaker: Dr. Ildiko Lingvay

For CME and MOC Credits as well as Instruction on How to Claim Credit please go to:
https://med.virginia.edu/cme/learning/uvarss/medgrmoc/

LEARNING OBJECTIVES:
1) Understand the current diabetes treatment guidelines
2) Understand how to select the best treatment for patients with diabetes

QUESTIONS:
1. Your 57 year old patient with type 2 diabetes is treated with metformin and has a HbA1c of 6.0%. He was recently admitted with an acute stroke. What changes would you recommend for his diabetes management?
   a) Nothing, his glycemic control is perfect
   b) Stop metformin, start a GLP-1 RA
   c) Continue metformin, start a GLP-1 RA
   d) Stop metformin, his diabetes is “cured”

2. The preferred glucose lowering class for patients with type 2 diabetes and heart failure with reduced ejection fraction is:
   a) SGLT2 inhibitors
   b) DPP IV inhibitors
   c) Insulin
   d) GLP-1 RA

3. My 47 y/o patient with type 2 diabetes and heart failure is currently treated with metformin, glimepiride and empagliflozin and her HbA1c is 7.9%. What should I do?
   a) Add insulin
   b) Add a DPP IV inhibitor
   c) Nothing, HbA1c of 7.9% is “good enough” considering this patient’s comorbidities
   d) Add a GLP-1 RA

4) True or FALSE – GLP-1 Receptor agonists are contraindicated in patients with heart failure
5) True or FALSE – SGLT 2 inhibitors increase glucagon level.
DISCLOSURES:

Research funding (paid to the institution): NovoNordisk, Merck, Novartis, GI Dynamics, Pfizer, Mylan
Research Related Consulting (paid to the institution): NovoNordisk
Consulting/Advisory Boards: Novo Nordisk, AstraZeneca, Boeringher-Ingelheimer, TARGETPharma, Intarcia, Valeritas, Lilly, Sanofi, Mannkind, Janssen
Other support (travel and/or publication support): NovoNordisk, AstraZeneca, Boeringher-Ingelheimer, Lilly, Sanofi, Merck, Pfizer

Current information is publicly available on the UT Southwestern Conflict of Interest site:
https://www.utsouthwestern.edu/research/research-administration/conflict-of-interest/public-disclosure.html